| Final analysis of the phase III study testing the role of PRoactivE coaching on PAtient REported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of checkpoint-inhibitor + axitinib in first line therapy (PREPARE; AIO-NZK-0115/ass; IAG-N) |
Viktor Grünwald |
Philipp Ivanyi |
| Oncol Res Treat 49 (suppl.1): 252 |
Abstract |
2026 |
|
Nierenzellkarzinom
|
PREPARE |
AIO-NZK-0115/ass |
| www.doi.org/10.1159/000550849 |
|
|
| Adjuvant Chemotherapy Alone or Combined with Atezolizumab in Patients with Stage III Deficient DNA Mismatch Repair (dMMR) Colon Cancer – Results of the Randomized ATOMIC Trial (Alliance A021502/AIO-KRK-0317) |
Dirk Arnold |
Frank Sinicrope |
| Oncol Res Treat 49 (suppl.1): 11-2 |
Abstract |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
ATOMIC |
AIO-KRK-0317 |
| www.doi.org/10.1159/000550849 |
|
|
| Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer |
Frank A. Sinicrope |
Jeffrey A. Meyerhardt |
| N Engl J Med 394(12): 1155-66 |
Vollpublikation |
2026 |
|
Kolon-/Rektum-/Dünndarmtumoren
|
Atomic |
|
| www.doi.org/10.1056/NEJMoa2507874 |
|
|
| Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung – An AIO phase Ib/II trial |
Martin Reck |
Martin Sebastian |
| Lung Cancer 214: 109318 |
Vollpublikation |
2026 |
|
Thorakale Onkologie
|
|
|
| www.doi.org/10.1016/j.lungcan.2026.109318 |
|
|
| Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216) |
Lutz MP |
Karthaus M |
| Br J Cancer 134:85-91 |
Vollpublikation |
2026 |
|
Pankreaskarzinom
|
|
AIO-PAK-0216 |
| doi.org/10.1038/s41416-025-03188-x |
|
|
| 1876P Effectiveness of Maintenance Therapy with Pembrolizumab vs. Pemetrexed and Pembrolizumab in Advanced Non-Small Cell Lung Cancer: Real-world data from the German Prospective CRISP Registry (AIO-TRK-0315) |
S. Heinzen |
M. Sebastian |
| Ann Oncol 36 (Suppl. 2): 1008-9 |
Poster |
2025 |
|
Thorakale Onkologie
|
CRISP Registry |
AIO-TRK-0315 |
| doi.10.1016/j.annonc.2025.08.2500 |
|
|
| 110P: Prediction of the individual risk for the development of brain metastases in patients with stage IV NSCLC without actionable genomic alterations – data from the German CRISP Registry (AIO‑TRK‑0315) |
F. Acker |
M. Sebastian |
| Journal of Thoracic Oncology 20 (3) (supplement 1): 79-80 |
Poster |
2025 |
|
Thorakale Onkologie
|
CRISP Registry |
AIO‑TRK‑0315 |
| doi.org/10.1016/S1556-0864(25)00305-3 |
|
|
| Interim Analysis of pulmonary tolerability from the multicenter ROSE Study: Radiation during Osimertinib Treatment Safety and Efficacy Cohort |
Amanda Tufman |
Diego Kauffmann-Guerrero |
| Eur Respir J 66 (suppl 69): PA6062 |
Poster |
2025 |
|
Thorakale Onkologie
|
ROSE |
|
| www.doi.org/10.1183/13993003.congress-2025.PA6062 |
|
|
| Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer |
Althoff FC |
Sebastian M |
| Future Oncol 21(29):3749-57 |
Abstract |
2025 |
|
Thorakale Onkologie
|
NeoTRACE |
|
| www.doi.org/10.1080/14796694.2025.2591213 |
|
|
| Role of pelareorep in activating anti-tumor immunity in PDAC |
Trauger R |
Coffey M |
| J Clin Oncol 43 (no. 16_suppl):2562 |
Abstract |
2025 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2025.43.16_suppl.2562 |
|
|
